Ascentage Presents Pivotal Lisaftoclax Data at ASH Meeting
In a registrational Phase II study of 77 patients with BTK inhibitor–refractory relapsed/refractory CLL/SLL, lisaftoclax monotherapy delivered a 62.5%...
Nurix Data Shows Durable, Deepening Response in CLL Trial
Objective response rate of 83% with two complete responses and a median progression-free survival of 22.1 months were reported...
Arvinas Data: ARV-393 & Glofitamab Show Synergy, Activity
In a humanized high-grade B‑cell lymphoma xenograft model, ARV‑393 combined with glofitamab delivered 81% tumor growth inhibition with concomitant...
Beam’s Risto-Cel Shows Durable Profile in Sickle Cell Trial
In updated Phase 1/2 data from 31 sickle cell disease patients treated with ristoglogene autogetemcel (risto-cel; formerly BEAM-101), mean...
Tuspetinib Triple Therapy Shows High AML Response Rate at ASH
In newly diagnosed AML patients ineligible for induction, tuspetinib plus venetoclax and azacitidine delivered a 90% CR/CRh rate across...
Quetzal Launches Phase III Trial for Leukemia Drug QTX-2101
No efficacy data were disclosed. Quetzal Therapeutics has opened a global, multicenter, randomized Phase III trial of QTX-2101, an...
Novabridge Presents Expanded Phase 1 Ragistomig Data at ESMO
NovaBridge’s Phase 1 expansion of ragistomig, a PD-L1 × 4-1BB bispecific, reports responses in patients previously non-responsive to checkpoint...
PainReform Starts Phase II Trial for OcuRing-K Eye Therapy
Preclinical work and a Phase 1 evaluation of OcuRing-K reported reductions in post-cataract pain and inflammation with lower total...
Empaveli Positive Phase 3 VALIANT Results Published in NEJM
Topline: In the Phase 3 VALIANT trial for C3 glomerulopathy and primary IC-MPGN, pegcetacoplan cut proteinuria by 68% versus...
Significant ALS Biomarker Results Support Clene’s CNM-Au8
CNM-Au8 produced statistically significant declines in neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) with signals that track...